Condition: Neoplasms · Tenosynovial Giant Cell Tumor · Sponsor: Abbisko Therapeutics Co, Ltd
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
This description comes directly from the study's public registry record.
YUAN LU · +86-21-68910052 · clinical@abbisko.cn
Siqing Fu, MD · (713)792-4318 · siqingfu@mdanderson.org
Always discuss trial participation with your own doctor first.
| Precision NextGen Oncology | Beverly Hills, California, United States | Active Not Recruiting |
| SCRI at HealthOne | Denver, Colorado, United States | Completed |
| The Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | Completed |
| MD Anderson Cancer Center | Houston, Texas, United States | Completed |
| Beijing Jishuitan Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Sun Yat-sen University | Guangdong, Guangzhou, China | Recruiting |
| Hebei Medical University Third Hospital | Shijiazhuang, Hebei, China | Completed |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Active Not Recruiting |
| The First Affiliated Hospital of Zhengzhou Universtity | Zhengzhou, Henan, China | Completed |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Active Not Recruiting |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | Active Not Recruiting |
| Liaoning Cancer Hospital | Shenyang, Liaoning, China | Completed |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04192344